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ABBREVIATION LIST 
ADA – American Diabetes Association 
BPD – Biliopancreatic Diversion 
BMI – Body Mass Index 
dBP – Diastolic Blood Pressure 
DLP – Dyslipidemia 
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T2DM – Type 2 Diabetes Mellitus 
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WHO – World Health Organization 
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 4 
ABSTRACT 
Introduction: Type 2 diabetes mellitus, high blood pressure and dyslipidemia are important 
cardiovascular risk factors associated with obesity. Bariatric surgery is effective in treating obesity 
and may influence the associated comorbidities, having been already included in the treatment 
recommendations for type 2 diabetes mellitus. 
Objectives: This review aimed to summarize the known effects of bariatric surgery on these 3 
important comorbidities associated with obesity. 
Methods: PubMed was the main source, namely the MeSH database. Out of 945 articles published 
in the last 5 years, 49 articles were selected. The articles were divided in 3 groups for separate analysis 
of each comorbidity. 
Conclusion: Bariatric surgery has great potential in managing obesity related comorbidities. The 
outcomes are best established for type 2 diabetes mellitus than for high blood pressure and 
dyslipidemia, but bariatric surgery has shown superiority to optimal medical treatment in all. 
Key Words: Bariatric surgery, Obesity, Type 2 diabetes mellitus, High blood pressure, Dyslipidemia, 
Metabolic outcomes 
RESUMO 
Introdução: Diabetes mellitus tipo 2, hipertensão arterial e dislipidemia são importantes factores de 
risco cardiovascular associados à obesidade. A cirurgia bariátrica é eficaz no tratamento da obesidade 
e pode influenciar as comorbilidades associadas, tendo já sido incluída nas recomendações para o 
tratamento de diabetes mellitus tipo 2. 
Objectivo: Esta revisão bibliográfica tem como objectivo sumariar os efeitos conhecidos da cirurgia 
bariátrica nestas 3 importantes comorbilidades associadas à obesidade. 
Métodos: o PubMed foi a principal fonte de informação, nomeadamente a base de dados MeSH. De 
945 aritgos publicados nos últimos 5 anos, 49 foram selecionados. Os artigos foram divididos em 3 
grupos para análise independente de cada comorbilidade. 
Conclusão: A cirurgia bariátrica tem grande potencial na abordagem de comorbilidades associadas 
à obesidade. Os resultados estão melhor demostrados para a diabetes mellitus tipo 2 do que para a 
hipertensão arterial e dislipidemia, mas a cirurgia bariátrica mostrou superioridade ao tratamento 
médico optimizado em todas as comorbilidades. 
Palavras-chave: Cirurgia bariátrica, Obesidade, Diabetes mellitus tipo 2, Hipertensão arterial, 
Dislipidemia, Alterações metabólicas  
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INTRODUCTION 
 Diabetes mellitus, HBP and DLP are cardiovascular risk factors with substantial impact and 
highly prevalent worldwide[1, 2] – according to the WHO the global prevalence of diabetes mellitus 
is around 8.5%[1], HBP is estimated to have a prevalence around 40% among adults[2] and DLP is 
estimated to be present in around 39% of the world’s adult population[2]. Obesity is associated to a 
higher risk of T2DM, HBP, DLP.[1, 3-7] For instance, HBP is the most common comorbidity in obese 
patients[8] and about 40% of morbidly obese patients have DLP.[9] 
 Lifestyle modification and medical therapy are the main tools available for managing 
obesity, T2DM, HBP and DLP but appropriate control is not easy to achieve, with only a minority of 
patients achieving control of all these diseases both individually and simultaneously.[5, 10, 11] 
 Bariatric surgery achieves substantial and sustained weight loss, it can improve the 
associated comorbidities[3, 5, 6, 12, 13] and after bariatric surgery there is a reduction in 
cardiovascular mortality.[9] Currently, the two most commonly used bariatric procedures are RYGB 
and SG[14, 15], with a higher increase in the use of SG than RYGB in recent years.[15-17] RYGB is 
considered the gold standard in bariatric surgery.[8, 17, 18] Other common procedure is GB[19], but 
its use has been decreasing in recent years.[15] There are some new procedures in study, including 
endoscopic procedures that are less invasive, but they are still under investigation before they can be 
considered as valid treatment options for obesity and its comorbidities.[15, 19] 
 The present recommendations for using bariatric surgery include all patients with BMI > 
40 kg/m2.[20] For patients with lower BMI, most agree that in patients with BMI > 35 kg/m2 and at 
least 1 obesity-related comorbidity, surgery should be offered, mainly if that comorbidity is not well 
controlled with medical therapy.[20] Not all recommendations agree, but some suggest surgery for 
patients with BMI 30–35 kg/m2 and a comorbidity poorly controlled with medical therapy predicted 
to respond to surgery.[20] As a treatment for T2DM, bariatric surgery follows these recommendations 
and it should be offered to diabetic patients with BMI ≥ 35 kg/m2[12, 14, 17, 21], especially if poorly 
controlled with optimal medical treatment, while for patients with mild obesity (30 kg/m2 ≤ BMI < 35 
kg/m2) the recommendations aren’t unanimous.[14] The BMI thresholds in these recommendations 
need to be adjusted for Asian populations[21] – BMI thresholds are lower in these populations (⋍2.5 
kg/m2). 
 Therefore, bariatric surgery may be an important therapeutic approach for obesity and 
obesity related comorbidities. This review aims to summarize the known effects of bariatric surgery 
on 3 important comorbidities – T2DM, HBP and DLP. 
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METHODS 
A search was performed on PubMed, using the MeSH Database. The following formula was 
used: ("Bariatric Surgery"[Mesh] OR "Bariatric Medicine"[Mesh]) AND ("Diabetes Mellitus, Type 
2"[Mesh] OR "Hypertension"[Mesh] OR "Dyslipidemias"[Mesh])." 
The articles were filtered to include only studies in the Human species and published in the 
last 5 years. This search gathered 945 results. Out of these 945 articles, 90 articles were selected after 
reading the abstract of every article. The main criteria for inclusion were articles in English language 
and articles on the outcomes of bariatric surgery regarding at least 1 of the 3 selected comorbidities. 
After reading the full text of the articles, 49 articles were selected. The remaining 41 articles 
were excluded for not following the specifications mentioned previously, for not being relevant for 
the present review and for referring to biochemical or anatomopathological changes after bariatric 
surgery without specifying the metabolic outcomes associated. 
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RESULTS 
T2DM 
 Bariatric surgery improves glycaemic control (evaluated by the levels of HbA1C), leading 
to a clinical improvement in the vast majority of patients with T2DM.[3, 5, 10, 14, 18, 19, 22-24] 
Surgical management of T2DM has proven to be superior to the optimal medical treatment 
(pharmacological treatment and lifestyle modification therapies currently available).[12, 14, 17, 18, 
23, 25-27] Bariatric surgery reduces the need for medication in managing T2DM[10, 14, 23] and, in 
some cases, achieves remission of the disease.[3, 11, 12, 18, 25] The effect of bariatric surgery on 
T2DM associated complications (diabetic nephropathy, diabetic neuropathy, diabetic retinopathy…) 
is not well known.[11] 
 Remission rates of around 75% have been described for RYGB[14, 28] – up until 2 years 
after surgery[29] – and bariatric surgery has been shown to have an OR above 8 for T2DM remission 
compared to optimal medical treatment.[12] 
 Yan et al.[7] analysed 6 RCTs comparing RYGB with medical treatment for obese patients 
with T2DM. Regarding T2DM remission, a significant difference was found between the 2 groups 
(over 55% in the RYGB group vs. no remission in the medical group). The reduction of HbA1C and 
medication use was also significantly higher in the surgical group but there was no significant 
difference in the reduction of FPG.  
 Mingrone et al.[30] randomised 60 patients with BMI ≥ 35 kg/m2 and T2DM for at least 5 
years in 3 groups – 1 group underwent BPD, another underwent RYGB and the last group underwent 
medical treatment. After 5 years of follow-up there was no remission in the medical group and BPD 
presented a remission rate of over 60%, compared to a remission rate of nearly 40% following RYGB. 
Independently of remission, over 40% in the RYGB group and almost 70% in the BPD group achieved 
HbA1C levels ≤ 6.5% with or without medication, compared to a little over 25% of patients in the 
medical group. Additionally, over 80% of the patients in the surgical groups achieved HbA1C < 7.0% 
with no or only little use of medication. The use of medication and insulin was significantly lower in 
the surgical groups. 
 Yska et al.[27] compared obese (BMI > 35 kg/m2) patients with T2DM that underwent 
different bariatric procedures (RYGB, SG and GB) with a matched control group. The surgical group 
had an 18-fold increase in the chance of T2DM remission, with a higher chance of remission for 
RYGB (RR > 40), followed by SG (RR > 15) and GB (RR ⋍ 7). HbA1C and FPG had significant 
reductions in the 1st year after surgery, compared to the medical group and medication use was 
significantly lower in the surgical group after 3 years of follow-up. 
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 Two meta-analysis by Cho et al.[16] and Li et al.[8] compared the effects of SG and RYGB 
on T2DM. Overall, higher rate of remission was reported for RYGB, but no statistically significant 
difference relatively to SG was found. However, in the paper by Cho et al.[16], when considering only 
the RCTs included, there was a slight advantage in remission rates 1 year after surgery for RYGB. 
 Schauer et al.[23] reported 3-year outcomes in 150 obese patients with poorly controlled 
T2DM (HbA1C > 7.0%) randomized for RYGB, SG or intensive medical therapy. The primary end-
point for this study was HbA1C ≤ 6.0% independently of medication use. After 3 years of follow-up, 
statistically significant differences between the two surgical groups comparing to the medical group 
were found. This difference was also found for other end-points – HbA1C ≤ 6.5% and ≤ 7.0%. Both 
surgical procedures achieved bigger, quicker and more sustained reductions in HbA1C, FPG and 
medication use. There were no significant differences in the reductions of HbA1C and FPG between 
patients with BMI < 35 kg/m2 and patients with BMI ≥ 35 kg/m2. When comparing the 2 surgical 
groups, RYGB had lower need of medication than SG, with a higher proportion of patients in the 
RYGB group not needing any medication. Schauer et al.[31] reported the 5-year outcomes for this 
population. At that time, the two surgical groups kept statistically significant differences compared to 
the medical group. Both surgical procedures kept their superiority in inducing reductions in HbA1C, 
FPG and medication use. Reduction of HbA1C was not significantly different between patients with 
BMI < 35 kg/m2 and patients with BMI ≥ 35 kg/m2. RYGB also kept a lower need for medication 
than SG, with a higher proportion of patients in the RYGB group not needing any medication. 
 Shoar et al.[32] analised mid and long-term metabolic outcomes for RYGB and SG – Mid-
term was considered for follow-up periods from 3 to 5 years and long-term was defined as a follow-
up period of 5 years or more. Regarding T2DM remission, no differences were found between the 2 
procedures in either follow-up period, with similar remission rates for RYGB and SG in both mid and 
long-term. 
 Nosso et al.[33] studied obese patients with T2DM that underwent RYGB or SG. After 
surgery, both insulin sensitivity and insulin secretion improved similarly for the 2 procedures, and no 
significant difference was found between both procedures. 
 Griffo et al.[34] published a paper that evaluated early changes in metabolic parameters, 2 
weeks after RYGB and SG. It detected significant reductions in FPG, and insulin resistance (HOMA-
IR), also with no significant differences between both surgical procedures. 
 Liu et al.[35] studied obese patients from a Chinese population who underwent SG. Total 
T2DM remission rates reached 70% at 5 years of follow-up and optimal glycaemic control was 
achieved in over 70%, with significant reductions in HbA1C. 
 Courcoulas et al.[36] compared health outcomes in severely obese patients with multiple 
comorbidities following RYGB and GB after 3 years of follow-up. This paper showed that RYGB 
had better results than GB in T2DM remission, but both procedures have proved to induce significant 
improvements in T2DM.  
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 Celik et al.[37] analysed the metabolic outcomes of a different procedure, DSIT, on obese 
patients (BMI > 35 kg/m2) with T2DM. He detected significant reductions in FPG, HbA1C and 
postprandial plasma glucose 1 year after surgery. 
 Several different definitions of T2DM remission have been used[14], mostly including 
HbA1C levels. This creates a bias in studying the remission rates after bariatric surgery because slight 
differences in the HbA1C values considered may impact greatly on the remission rates found[12, 14, 
26] – for instance, reducing the threshold of remission from HbA1C levels of 6.0% to 5.7% can reduce 
the remission rates in half.[14] Table I presents an overview of the articles analysed and the main 
information reported regarding T2DM remission. 
 Remission of T2DM is dependent of other factors, beginning with the surgical procedure 
chosen – most studies report the best results for BPD[14, 15, 17, 18, 38] – some modifications of this 
procedure, like SIPS surgery, have been proposed with good results[15]; RYGB is considered to have 
good results, even in patients with advanced disease[25], despite having lower remission rates than 
BPD[14, 18, 38]; SG has lower remission rates than RYGB[11, 12, 14, 17-19, 25], but higher than 
GB[11, 14, 17, 18, 27] – one of the main advantages of GB is its reversibility[4] and although GB is 
considered a less invasive method, with smaller chance of complications, there is a high rate of 
reoperation for adjustment and removal, undermining its other big advantage.[25]. 
 Other factor is the severity of the disease prior to surgery, with lower rates of remission for 
patients with advanced disease[25] (longer disease duration[3, 11, 12, 14, 18, 39], higher HbA1C[39, 
40], lower C-peptide levels[18, 40], preoperative use of insulin[18, 40], …). Some studies have 
detected %EWL[3, 11] and BMI[39] as predictors of remission, but others showed that T2DM 
remission is independent of weight loss[10] and preoperative BMI[26, 39]. Some studies also suggest 
that older age may reduce the chance of remission.[18, 39, 40] Recently, there are some studies that 
suggest abdominal circumference as a better predictor for T2DM remission than BMI.[18, 26, 38] 
 Chen et al.[18] reported the impact of RYGB in T2DM patients and found clinical 
improvement in over 75% of patients after RYGB surgery. This study identified some factors that 
influence remission rates, with higher remission detected for higher preoperative C-peptide levels and 
for lower T2DM duration, age, insulin use, preoperative FPG and preoperative HbA1C. Additionally, 
lower total cholesterol, TG and LDL and higher HDL were shown to increase remission rates, as well 
as lower prevalence of HBP. The authors also found that lower waist circumference was associated to 
higher remission rates, unlike BMI, which didn’t significantly alter the remission rates. 
 Palmisano et al.[39] aimed to identify preoperative predictors of T2DM remission 1 year 
after RYGB. There was a decrease in HbA1C in all patients, with remission rates around 60% after 1 
year of follow-up. The patients were divided in 2 groups according to preoperative HbA1C levels. 
The cut-off for these groups was the mean preoperative HbA1C (7.8%). The preoperative predictive 
factors identified were BMI > 50 kg/m2 and low preoperative HbA1C (< 7.8%). 
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 Panunzi et al.[38] published a meta-analysis that aimed to compare T2DM remission in 
diabetic patients with BMI ≥ 35 kg/m2 and diabetic patients with BMI < 35 kg/m2 and also to identify 
predictors of that remission. The 3 main conclusions of this study were that: 1) bariatric surgery 
induces similar clinical improvement of T2DM in both BMI groups; 2) the reduction in HbA1C levels 
is independent of preoperative BMI; and 3) decrease in HbA1C levels is inversely related with 
abdominal circumference. The study concludes that BMI is not a good eligibility criteria for bariatric 
surgery. 
 Another paper by Panunzi et al.[26] merged the SOS study database with 2 RCTs and 
obtained 2 groups of patients – the 1st included obese patients with T2DM that underwent medical 
treatment and the 2nd included obese patients with T2DM that underwent bariatric procedures –, 
followed for 2 years. Remission rates were significantly higher in the surgical group (over 60% vs. 
15% in the medical group). There were no differences for different types of bariatric procedure in both 
remission and glycaemic control. The overall predictive factors for higher T2DM remission for both 
groups were younger age, shorter duration of T2DM, lower preoperative FPG and lower preoperative 
use of medication. When divided in 3 groups according to BMI (≤ 35 kg/m2, 35–40 kg/m2 and > 40  
kg/m2), there was significant difference between the group with BMI ≤ 35 kg/m2 and the group with 
>40 kg/m2 (OR = 2.9, favourable for BMI > 40 kg/m2), but not between BMI ≤ 35 kg/m2 and BMI 
35–40 kg/m2. This study suggests abdominal circumference could replace BMI as the main eligibility 
criteria for bariatric surgery. 
 Park et al.[40] also tried to identify predictors of T2DM remission following RYGB. 4 
predictive factors of T2DM remission after RYGB were identified: preoperative C-peptide levels and 
%TWL after surgery had a direct correlation with T2DM remission, while age in the moment of 
surgery and preoperative HbA1C levels were inversely correlated with remission. This study proposed 
a decision tree model (Figure 1) based on the preoperative predictors, and found C-peptide levels to 
be the most discriminating variable for T2DM remission – in this cohort, C-peptide > 2.6 ng/dL was 
mandatory to achieve T2DM remission –, followed by BMI and, finally, insulin use 
 Zenti et al.[41] studied obese patients (mean BMI > 45 kg/m2) with T2DM who underwent 
RYGB, SG and GB and analysed predictors of T2DM remission in that population. Younger age, 
shorter duration of T2DM and lower HbA1C (< 7.0%) were associated with higher remission rates. 
Remission rates were lower for GB than for the other procedures, with no significant difference 
between RYGB and SG. 
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Article Type of study 
Number 
of 
patients 
Surgical 
procedures 
studied 
Remission criteria 
Remission 
rates (%) 
Follow-up 
period 
Yan et al.[7] Meta-analysis 410 RYGB Not consensual among the studies analysed ⋍ 57 1 – 5 years 
Mingrone et al.[30] RCT 60 BPD, RYGB HbA1C < 6.0% and no medication 50 5 years 
Yska et al.[27] Retrospective 2 450 
RYGB, SG, 
GB 
HbA1C < 6.0% and no medication 94.5 a 2.4 years f 
 Cho et al.[16] Meta-analysis 857 RYGB, SG Not consensual among the studies analysed 73; 80 b 1 year 
Li et al.[8] Meta-analysis 18 449 RYGB, SG HbA1C < 6.5%, FPG < 126 mg/dL and no medication ⋍ 77 1.5 – 60 months 
Schauer et al.[23] RCT 137 RYGB, SG HbA1C ≤ 6.0% 38; 24 b 3 years 
Schauer et al.[31] RCT 134 RYGB, SG HbA1C ≤ 6.0% 29; 23 b 5 years 
Shoar et al.[32] Meta-analysis 5 264 RYGB, SG Not defined 82; ≥ 76 b > 3 years 
Nosso et al.[33] Prospective 33 RYGB, SG 
HbA1C < 6.0%, FPG < 100 mg/dL and no medication 
(complete), HbA1C < 6.5%, FPG < 125 mg/dL and no 
medication (partial) 
> 85; 75 b 1 year 
Liu et al.[35] Prospective 140 SG 
HbA1C < 6.5%, FPG < 100 mg/dL and 1 year without 
medication (complete), HbA1C < 6.5%, FPG < 126 
mg/dL and 1 year without medication (partial) 
70 5 years 
Courcoulas et al.[36] Prospective 2 348 RYGB, GB Not defined ⋍ 68; 29 c 3 years 
Celik et al.[37] Retrospective 159 DSIT Not defined > 85 18 months f 
Chen et al.[18] Meta-analysis 924 RYGB HbA1C < 5.7%, FPG < 100 mg/dL and no medication 50; 90d 6 – 24 months 
Palmisano et al.[39] Prospective 771 RYGB Not defined 58 1 year 
Panunzi et al.[26] Meta-analysis 727 
BPD, RYGB, 
SG, GB 
FPG < 100 mg/dL and no medication ⋍ 65 2 years 
Park et al.[40] Retrospective 134 RYGB 
HbA1C < 6.0% and no medication (complete), HbA1C 
< 6.5% and no medication (partial) 
45; 15e 12 months e 
Table I – Summary of T2DM remission rates found in the articles analysed 
a – In this study remission rates was calculated as number of remissions per 1 000 person-years. 
b – Remission rates were analysed independently for RYGB (higher value) and SG (lower value). 
c – Remission rates were analysed independently for RYGB (higher value) and GB (lower value). 
d – Remission rates were analysed separately for preoperative insulin users (lower value) and patients with no prior insulin use (higher value). 
e – Remission rates were analysed independently for complete remission (higher value) and partial remission (lower value). 
f – Only mean follow-up was reported. 
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 Some authors proposed metabolic scores to define if there is indication for bariatric 
surgery[10] Some proposed predictive scores of T2DM remission following bariatric surgery, and a 
few have been validated[40], as the ABCD Score[42] (Table II) – with a range from 0 to 10, with 
higher chance of T2DM remission for higher scores, validated to Asian populations – and DiaRem 
Score[43] (Table III) – ranging from 0 to 22, with higher scores corresponding to lower probability of 
T2DM remission following RYGB. 
 
Variable 
Points 
0 1 2 3 
Age (years) ≥ 40 < 40 – – 
BMI (kg/m2) < 27 27–34.9 35–41.9 ≥ 42 
C-peptide (ng/ml) < 2 2–3.9 4–6 > 6 
T2DM duration (years) > 10 5–10 2–4.9 < 2 
Table II – ABCD Score[42] 
 
 Some studies in patients with lower BMI (30 kg/m2 ≤ BMI < 35 kg/m2) have shown that 
bariatric surgery maintains superiority as a treatment option for T2DM compared to optimal medical 
treatment in mildly obese patients with T2DM.[12, 18, 25, 44] Some studies report lower remission 
rates in these patients (up to 50% vs. 75%[14]) when compared with morbidly obese patients (BMI > 
40 kg/m2)[14], while others show that there’s no significant difference.[10, 44] Independently of 
remission, the changes in FPG and HbA1C after RYGB follow similar patterns in both clusters.[14] 
Some of these studies, conducted in Asian populations, may induce some bias in recommending 
bariatric surgery for patients with lower BMI values, because in these populations the BMI thresholds 
for the classifications of obesity are lower, which means that Asian patients with BMI considered as 
mild obesity in Western countries may, in fact, correspond to severe or morbidly obese patients.[14] 
 Cummings et al.[45] published a RCT comparing RYGB with ILMI in obese patients (BMI 
30–45 kg/m2) with T2DM. Remission of T2DM was defined as HbA1C < 6.0% with no use of 
medication. After 1 year of follow-up, remission rates were significantly different (60% for RYGB 
vs. < 6% for ILMI), with an OR of remission reaching nearly 20 for RYGB compared to ILMI. 
Reductions in HbA1C and FPG were not significantly different but after RYGB medication use was 
significantly lower for the surgical group, as well as insulin use (even with higher baseline insulin use 
in the surgical group). 
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 Points 
Age (years)  
< 40 0 
40–49 1 
50–59 2 
≥ 60 3 
HbA1C (%)  
< 6.5 0 
6.5–6.9 2 
7.0–8.9 4 
≥ 9.0 6 
Treatment with insulin  
No 0 
Yes 10 
Other medications  
No sulfonylureas or insulin-sensitising agent other than metformin 0 
Sulfonylureas and insulin-sensitising agent other than metformin 3 
Table II – DiaRem Score[43] 
 Another RCT by Courcoulas et al.[46] compared RYGB and GB with LWLI in obese (30 
≤ BMI < 40) patients with T2DM. Partial remission (HbA1C < 6.5% and FPG ≤ 125 mg/dL with no 
medication) and total remission (HbA1C < 5.7% and FPG ≤100 mg/dL with no medication) were 
assessed. Overall remission (partial or complete) was higher for RYGB than GB (40% vs. 29%) and 
there was no remission with LWLI. Complete remission was also higher for RYGB (15% vs. 5%).The 
authors detected no significant difference between obesity classes (Class I – 30 ≤ BMI < 35 – vs. Class 
II – 35 ≤BMI < 40) in HbA1C and FPG reductions. There was a lower need for medication in patients 
that underwent bariatric surgery with a significant number of patients with no use of medication after 
surgical treatment (72% after RYGB vs. 45% after GB), opposing to no patients without medication 
after LWLI. 
 Ikramuddin et al.[47] published a RCT in which 120 patients with BMI 30–40 kg/m2 with 
T2DM for at least 6 months, HbA1C ≥ 8.0% and C-peptide > 1.0 ng/mL were randomized to receive 
RYGB or medical treatment. In this study, the primary outcome included 3 metabolic parameters – 
HbA1C < 7.0%, LDL < 100 mg/dL and sBP < 130 mmHg. There was a significant difference in 
achieving this outcome after 1 year of follow-up (49% after RYGB vs. 19% in the medical group), 
with an OR of nearly 5, favourable to RYGB. Separate analysis of each parameter of the primary 
outcome at 1 year of follow-up showed only significant difference regarding HbA1C (75% after 
RYGB vs. 32% for the medical group), with an OR of 6, also favourable to RYGB. FPG reduction 
was also higher after RYGB and in the RYGB group there was a lower need for T2DM medication. 
Another paper by Ikramuddin et al.[48] reported the 2 year outcomes of this RCT. The differences for 
primary outcome and its parameters found at 1 year follow-up were maintained, with a slight decrease 
of the number of patients that achieved the primary outcome in both groups. Mean FPG was 
significantly lower in the RYGB group. 12% of the RYGB group patients that achieved the primary 
outcome at 2 years where using no medication.  
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Figure 1 – Decision tree model for T2DM remission following RYGB by Park et al. (2015)[40] 
 
 Xu et al.[44] analysed RYGB outcomes in T2DM patients and compared these outcomes 
between patients with class I obesity and patients with class II or III obesity during 3 years of follow-
up. Complete remission was defined as HbA1C < 6.0% and FPG < 100 mg/dL, partial remission was 
defined as HbA1C < 6.5% and FPG 100–125 mg/dL and good glycaemic control was obtained if 
HbA1C < 7.0% and no use of medication was mandatory to define each of these end-points. Both 
obesity class groups showed similar evolution of multiple metabolic parameters. Partial remission was 
similar in the 2 groups in all points of follow-up. Complete remission was significantly higher for the 
group with more severe obesity at 1 and 2 years of follow-up, but there was no difference in the 3-
year evaluation. HbA1C and FPG were significantly lower in the group with more severe obesity 
compared to the group of obesity class I patients. 
 Hsu et al.[49] analysed patients with BMI < 35 kg/m2 and T2DM that underwent bariatric 
surgery (RYGB and SG) and compared them to a group with matched characteristics that underwent 
medical treatment. Complete remission was defined as FPG < 110 mg/dL and HbA1C < 6.0% with 
no use of medication and partial remission was defined as FPG 110–126 mg/dL and HbA1C 6.0–6.5% 
without medication. HbA1C reduction after 5 years of follow-up was significantly higher in the 
surgical group, as well as partial and complete remission (28% vs. 1.6% and 36% vs. 1.2%, 
respectively).  
C-peptide ≤ 2.6 ng/dL
No
BMI ≤42.5 kg/m2
Yes
Insulin use
Yes
Non-remission 
(0.31-15.7%)
No
Remission (0.66-
53.9%)
No
Remission (0.96-
22.5%)
Yes
Non remission (0.0-
7.8%)
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 Lee et al.[50] compared the outcomes of bariatric surgery in non-obese (BMI < 30 kg/m2) 
Asian patients with T2DM and obese (BMI > 30 kg/m2) Asian patients with T2DM and investigated 
the predictors of T2DM remission. The definition for total remission was HbA1C < 6.0% with no use 
of medication and for partial remission was HbA1C < 6.5% with no medication. 1 year after surgery 
non-obese patients had total remission rates of 25% and partial remission rates of nearly 50%. 
Compared to obese subjects the total remission rates were lower. The ABCD Score was used, and 
proved to predict T2DM remission in non-obese patients. 
 Dixon et al.[4] analysed the outcomes of a new GB system, “LAP BAND”, in patients with 
BMI between 30-40. Only 5 patients with T2DM were included and 4 were using medication at 
baseline. After 5 years of follow-up all were off medication and significant decreases in both HbA1C 
and FPG were reported for all patients. 
 Bariatric surgery has also been suggested for adolescents[51-53], particularly if 
comorbidities are present – for instance, T2DM with onset during adolescence is more aggressive than 
if it has onset during adulthood[52] and disease control is harder to achieve.[52] It seems to have 
greater potential to induce weight loss and revert the obesity related comorbidities in this age group 
than in adults, mainly in the short to medium term.[51-53] However, there are still not many studies 
of long term outcomes in this age group.[51-53] The most used bariatric procedures used in 
adolescents are, similarly to adults, RYGB and SG[51, 53] – RYGB has some advantage compared to 
SG because of its reversibility.[53] 
 Inge et al.[51] studied adolescents (age ≤ 19 years) with BMI > 30 kg/m2 that underwent 
bariatric surgery (RYGB and SG). A significant weight loss was obtained for both procedures. Among 
adolescents with T2DM, the remission rates reached 95% at 3 years of follow-up and prediabetes had 
remission rates of over 75%. 
 Vilallonga et al.[53] studied the outcomes of RYGB in obese (BMI > 40 kg/m2 or BMI > 
35 kg/m2 with an associated comorbidity) adolescents (age < 18 years). 19 adolescents were paired 
with a matched control group of adults, with a mean follow-up > 7 years in both groups. All patients 
with T2DM in both groups achieved remission. 
 Aminian et al.[22] analysed the metabolic outcomes in patients with failed bariatric surgery 
(patients that didn’t achieve %EWL of at least 25% after a follow-up of 5 years or more) and they 
concluded that although bariatric surgery was not successful in achieving a significant and sustained 
weight loss in some patients, it kept its advantages regarding not only T2DM – with a remission rate 
of 23% and a clinical improvement in 42% of patients – but also in HBP and DLP (discussed ahead). 
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 In studies with longer follow-up periods, a relapse of T2DM in patients that achieved 
remission was described[19] – with a 5 year relapse rate of up to one third of the patients that 
achieved remission after bariatric surgery[54], which can reach half of the patients with longer 
follow-up.[12, 29] This relapse is dependent of the age of the patients – higher relapse in older 
patients[54] – and also of the disease severity before surgical treatment – higher relapse rates among 
patients who had more advanced disease[25] (longer duration of disease[3, 11, 54], insulin use 
previously to surgery[54] and poorer preoperative glycemic control[54]). Other factors that 
influence this relapse have been detected in some studies, and include lower %EWL[3, 11] and 
weight regain (BMI increase ≥ 5 kg/m2 compared to maximum weight loss achieved).[3, 11] This 
long term phenomenon highlights the importance of long term monitoring of diabetic patients that 
underwent a bariatric procedure in order to prevent relapse.[7, 14, 25, 29, 30] Some authors go 
further in these prevention measures and propose the use of metformin after bariatric procedures 
(because it has no risk of hypoglycaemia or weight gain).[25] However, even in patients with T2DM 
relapse after bariatric surgery, glycaemic control is easier to achieve[14], which translates in lower 
use of medication[11, 12, 14], and there are other metabolic improvements in both HBP and 
DLP[11] (revealed below). 
 Regarding health care costs, there aren’t many studies that analysed this aspect of bariatric 
surgery because it requires studies with long term follow-up of diabetic patients that underwent 
bariatric surgery, which are still scarse.[14] According to Keating et al.[55] – who assessed the costs 
of bariatric surgery compared to medical treatment over a follow-up period of 15 years, based on the 
SOS study data –, it seems there is no significant difference between surgical and medical treatment 
in patients with T2DM.[14, 55] In patients with euglycaemia or prediabetes, the total health care costs 
are significantly higher for the surgical treatment.[14, 55] However, further investigations are needed 
to be able to accurately define which strategy is economically most advantageous.[14, 55] 
 Tang et al.[56] analysed the cost-effectiveness of bariatric surgery for T2DM compared to 
medical treatment. The bariatric procedures studied were RYGB and SG. This study concluded both 
procedures are cost-effective compared to medical treatment, with a slight advantage for SG. 
However, this study only considered a period of 2 years, so further studies regarding the long term 
costs of bariatric surgery are needed. 
 Some studies have suggested that bariatric surgery may have a protective effect on obese 
patients with impaired FPG, reducing the risk of developing T2DM.[10] 
  
 17 
HBP 
 Bariatric surgery achieved clinical improvements in HBP[3, 6, 18, 22, 28, 54], and has 
potential to revert this disease[28, 54] – defined as normal BP (sBP < 140 mmHg and dBP < 90 
mmHg) without the use of antihypertensive medication. Remission rates 1 year after surgery are 
significant, with remission in around two thirds of patients [54] and only a minority of patients without 
improvement in BP levels at this point (around 10%)[54].  
 Pedersen et al.[6] analysed early BP changes following RYGB. They performed 24h 
ambulatory BP measurements in obese patients (BMI 35-50 kg/m2) preoperatively, 1 and 10 days after 
RYGB. 20 patients were studied, with a preoperative rate of HBP of 50%. Antihypertensive 
medication was maintained after surgery in patients with HBP. Baseline characteristics of both groups 
were similar. 1 day after surgery no difference was reported in dBP, sBP or MAP in both groups. 10 
days after surgery there was a significant reduction in sBP for both groups, and dBP also decreased 
significantly in the preoperative HBP group, although there was a slight decrease in the normotensive 
group as well (p=0.058). MAP was also significantly lower in both study groups. No statistically 
significant differences were identified between the 2 groups in all the BP measurements made in the 
3 moments evaluated. No relationship between weight change and 24h MAP change was found in any 
of the groups neither for the total population of the study. 
 Mingrone et al.[30], reported reductions in both dBP and sBP in all 3 groups studied (BPD, 
RYGB and medical treatment), but without statistical significance. The only significant difference 
was found in the medical group, which had a higher need for medication use than the 2 surgical groups 
at 5 years of follow-up. Yska et al.[27] also found a significant reduction in antihypertensive 
medication use following RYGB after 5 years of follow-up. 
 Schauer et al.[23] reported 3-year outcomes in 150 obese patients with poorly controlled 
T2DM randomized for RYGB, SG or medical therapy. No significant differences in BP levels were 
found among the 3 groups studied. Similarly to other studies, both surgical groups had a lower need 
for antihypertensive medication than the medical group. Schauer et al.[31] described the 5-year 
outcomes for this population and the same findings for HBP were found. 
 Yan et al.[7] reported, regarding BP, a significant reduction in sBP in the RYGB group, 
compared to the medical group, as well as a reduction in antihypertensive medication use. No 
significant difference in dBP was found in both groups. 
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Article Type of study 
Number 
of 
patients 
Surgical 
procedures 
studied 
Follow-up 
period 
Significant changes found 
Pedersen et al.[6] Prospective 
22 
RYGB 
1 day No changes 
20 10 days 
Decrease in sBP and MAP; Decrease in dBP in patients with preoperative 
HBP 
Mingrone et al.[30] RCT 60 BPD, RYGB 5 years Lower need for antihypertensive medication following surgery 
Yska et al.[27] Retrospective 569 
RYGB, SG, 
GB 
1 year Significant reductions in BP levels following RYGB 
5 years Lower need for antihypertensive medication following RYGB 
Schauer et al.[23] RCT 137 RYGB, SG 3 years Lower need for antihypertensive medication following surgery 
Schauer et al.[31] RCT 134 RYGB, SG 5 years Lower need for antihypertensive medication following surgery 
Yan et al.[7] Meta-analysis 410 RYGB 1 – 5 years Significant reductions in sBP and medication use following RYGB 
Shoar et al.[32] Meta-analysis 552 RYGB, SG > 3 years HBP remission in ⋍ 62% following RYGB and ⋍ 57% following SG 
Li et al.[8] Meta-analysis 1 552 RYGB, SG 
1.5 – 60 
months 
HBP remission in 60% following RYGB and ⋍ 51% following SG 
Liu et al.[35] Prospective 140 SG 5 years Clinical improvement of HBP in ⋍ 50% of patients 
Celik et al.[37] Retrospective 121 DSIT 18 monthsa HBP remission ⋍ 95% in patients with BMI > 35 kg/m2, T2DM and HBP 
Table IV – Overview of HBP changes reported in the articles analysed 
a – Only mean follow-up was reported. 
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 Shoar et al.[32] compared mid and long-term outcomes for RYGB and SG, has shown no 
significant differences in HBP remission between RYGB and SG in both periods. 
 On the contrary, Li et al. [8] analysed 21 studies that mentioned HBP remission, and found 
significantly higher remission rates for RYGB compared to SG. 
 Liu et al.[35] reported clinical improvements after SG in around 50% of the patients with 
HBP. 
 Courcoulas et al.[36] reported better results for RYGB than GB in HBP remission. 
 The study by Celik et al.[37] analysing metabolic outcomes following DSIT, detected a 
remission rate of around 95% in patients with BMI > 35 kg/m2, T2DM and HBP. 
 Table IV presents a summary of the articles studied and the main information reported 
regarding HBP outcomes. 
 Similarly to T2DM, some studies have analysed the outcomes of bariatric surgery on mildly 
obese patients.  
 The RCT by Cummings et al.[45] has also shown significant decrease in sBP after RYGB 
compared to ILMI, but it reported no significant change in dBP in both groups. 
 Courcoulas et al.[46] published a RCT that has shown improvements in both sBP and dBP. 
Decrease in sBP was more significant for RYGB compared to GB and LWLI 3 years after treatment 
and decrease in dBP was more significant for RYGB compared to GB 3 years after surgery. 
 Another RCT by Ikramuddin et al.[47] has shown that RYGB led to a lower need of 
antihypertensive medication and a significant reduction in dBP compared to medical treatment at 1 
year of follow-up. The paper by Ikramuddin et al.[48] reported lower mean BP in the RYGB group 
and although the proportion of patients that achieved sBP < 130 mmHg was not significantly different 
in both groups, there was a significant higher number of patients that achieved this BP goal in the 
RYGB group with no use of medication. 
 The article by Dixon et al.[4] has reported a sustained decrease in sBP from 1 to 5 years of 
follow-up after GB in patients with BMI 30-40 kg/m2 and a reduction in antihypertensive medication 
use at 5 years of follow-up. 
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 The factors that have been described to predict this remission are related to the severity of 
the disease: lower number of antihypertensive medications used prior to surgery and shorter duration 
of disease are associated with higher remission rates.[54] Younger age has also been described as a 
predictor of remission but that finding is not consensual among studies.[54] The surgical procedure 
doesn’t seem to affect these outcomes (RYGB vs. SG vs. GB).[54] 
 Even if remission in not obtained, there is a significant improvement in both dBP and sBP 
after bariatric surgery.[11] 
 As described for T2DM, bariatric surgery seems to have great potential in reverting obesity 
related comorbidities in adolescents.[51-53] 
 Inge et al.[51] has reported a remission rate for HBP of nearly 75% in obese adolescents 3 
years after either RYGB or SG. 
 Similarly, Vilallonga et al.[53] studied the outcomes of RYGB in obese adolescents paired 
with a matched control group of adults. All patients with HBP in both groups achieved remission 7 
years after surgery. 
 In the context of failed bariatric surgery (%EWL < 25% after a follow-up ≥ 5 years), these 
beneficial effects are still present, as reported by Aminian et al.[22] where there was a significant 
reduction in sBP after failed bariatric surgery, with 58% of patients achieving the treatment goals 
defined by the ADA – sBP < 130 mmHg and dBP < 80 mmHg. 
 A relapse of HBP in patients that achieved remission after surgery has been described[54], 
with relapse rates of around 20% after 3 years of follow-up.[54] This relapse is associated with a 
higher number of antihypertensive medications used prior to surgery[54], lower %EWL in the 1st year 
after bariatric surgery[54] and weight regain.[3] 
 Additionally, bariatric surgery seems to have a protective effect on obese patients without 
HBP prior to surgery.[54] 
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DLP 
 Bariatric surgery has been shown to induce clinical improvements in patients with DLP[3, 
5, 18, 22, 28], sometimes achieving reversion of this disease – normal plasma lipids profile without 
the use of medication.[9, 28, 37] 
 Some studies have shown significant reduction in TG and LDL levels, as well as a 
significant increase of HDL levels.[3, 11] 
 Carswell et al.[9] studied the effect of RYGB on plasma lipid levels and reported significant 
decreases in total cholesterol levels (from the 1st month after surgery up to 2 years of follow-up), LDL 
cholesterol levels (from the 1st month after surgery up to 2 years of follow-up) and TG levels (from 
the 3rd month after surgery up to 2 years of follow-up) and significant increases in HDL cholesterol 
levels (from 12 months after surgery up to 2 years of follow-up) and NEFA (from the 1st month after 
surgery until the 3rd month of follow-up, with no further changes compared to preoperative levels). 
This paper compared the effects of statins and RYGB and concluded that the surgical procedure had 
more favourable effects than the pharmacological therapy – statins can lower total cholesterol, LDL 
and TG levels up to 20%, 28% and 13%, respectively, and increase HDL up to 5% vs. a reduction of 
total cholesterol, LDL and TG of 16%, 21% and 36%, respectively, and 11% increase in HDL 
following RYGB. 
 Mingrone et al.[30] compared BPD, RYGB and medical treatment and found significant 
differences for the surgical groups in reducing total cholesterol, LDL and TG levels comparably to 
the medical group, particularly after BPD. Increase in HDL levels was reported in all 3 groups, with 
a more pronounced effect after RYGB. 
 Yska et al.[27] found significant reductions in TG levels 1 year after RYGB compared to 
medical treatment. After 5 years of follow-up there was a significant reduction in lipid-lowering 
medication following RYGB. 
 Yan et al.[7] detected reductions in TG and LDL and increase in HDL following RYGB, 
compared to the medical group, as well as lower lipid-lowering medication use. 
 Nosso et al.[33] compared RYGB and SG and only found significant decreases in total 
cholesterol and LDL following RYGB. 
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Article Type of study 
Number 
of 
patients 
Surgical 
procedures 
studied 
Follow-up 
period 
Significant changes found 
Carswell et al.[9] Meta-analysis 7 815 RYGB 
1 – 48 
months 
Sustained decreases in total cholesterol, LDL and TG; Sustained increase in 
HDL and temporary increase in NEFA 
Mingrone et al.[30] RCT 60 BPD, RYGB 5 years Reduction of total cholesterol, LDL and TG and increase of HDL 
Yska et al.[27] Retrospective 569 
RYGB, SG, 
GB 
1 year Decrease in TG levels 
5 years Lower need for lipid-lowering medication following surgery 
Yan et al.[7] Meta-analysis 410 RYGB 1 – 5 years 
Significant reductions in TG and LDL, increase of HDL and lower lipid-
lowering medication use following RYGB 
Nosso et al.[33] Meta-analysis 552 RYGB, SG > 3 years Decreases in total cholesterol and LDL following RYGB 
Li et al.[8] Meta-analysis 1 269 RYGB, SG 
1.5 – 60 
months 
DLP remission in ⋍ 71% following RYGB and ⋍ 50% following SG 
Schauer et al.[23] RCT 137 RYGB, SG 3 years Significant reductions in TG and increase of HDL and lower lipid-lowering 
medication use following surgery Schauer et al.[31] RCT 134 RYGB, SG 5 years 
Shoar et al.[32] Meta-analysis 798 RYGB, SG > 3 years 
DLP remission in ⋍ 55% following RYGB and ⋍ 48% following SG and 
hyper-TG remission in ⋍ 58% following RYGB and SG 
Griffo et al.[34] Prospective 25 RYGB, SG 2 weeks 
Reductions in fasting total cholesterol, TG, LDL and HDL levels and in 
postprandial total cholesterol, TG and HDL levels 
Liu et al.[35] Prospective 140 SG 5 years Clinical improvement of DLP in > 45% of patients 
Courcoulas et 
al.[36] 
Prospective 2 348 RYGB, GB 3 years 
DLP remission in ⋍ 62% following RYGB and ⋍ 27% following GB, Low 
HDL remission in ⋍ 86% following RYGB and ⋍ 68% following GB and 
hyper-TG remission in ⋍ 86% following RYGB and ⋍ 62% following GB 
Celik et al.[37] Retrospective 144 DSIT 1 year 
Decreases in TG, LDL and VLDL; DLP remission > 90% in patients  with 
BMI > 35 kg/m2, T2DM and DLP 
Table V – Summary of DLP changes reported in the articles studied 
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 Li et al.[8] compared DLP remission following RYGB and SG, and found superiority for 
RYGB in inducing DLP remission. 
 Schauer et al.[23] reported 3-year outcomes in 150 obese patients with poorly controlled 
T2DM randomized for RYGB, SG or intensive medical therapy. Significant reduction in TG and 
increase in HDL in both surgical groups compared to the medical group was found, as well as a lower 
need for lipid-lowering medication in both surgical groups. The complementary publication[31] 
reporting the 5-year outcomes for this population showed no differences between the 2 periods. 
 Shoar et al.[32] compared mid and long-term outcomes for RYGB and SG and found no 
significant differences in DLP remission between RYGB and SG in both periods. Additionally, there 
were some studies that analysed the mid-term effects of these procedures in TG levels, and no 
difference was found between RYGB and SG for mid-term reduction of TG. 
 Griffo et al.[34] described reductions in fasting total cholesterol, TG, LDL and HDL and in 
postprandial total cholesterol, TG and HDL levels 2 weeks after surgery, with no difference between 
RYGB and SG. The authors reported that the short term decrease in HDL was later compensated, with 
an overall increase in HDL 1 year after surgery. 
 Liu et al.[35] found clinical improvements in plasma lipid levels in over 45% of patients 
with DLP following SG. 
 Courcoulas et al.[36] detected better results following RYGB than the ones obtained after 
GB in DLP reversion, with significant decrease in TG and increase in HDL for both procedures. 
 Celik et al.[37] analysed metabolic outcomes following DSIT and found significant 
decreases in LDL, VLDL and TG after 1 year of follow-up and a remission rate of DLP over 90% for 
patients that underwent DSIT who had preoperative BMI > 35kg/m2, T2DM and DLP. 
 Table V presents a summary of the articles analysed and the main information obtained 
regarding DLP outcomes. 
 No predictors for DLP remission were described in any of the papers analysed. 
 Like in T2DM and HBP, some studies analysed DLP outcomes after bariatric surgery in 
mildly obese patients (BMI < 35 kg/m2). 
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 The RCT by Cummings et al.[45] reported reductions of TG in both RYGB and ILMI 
groups with no significant differences, as well as an increase of HDL in both groups, with a borderline 
non-significant difference between RYGB and ILMI (p=0.08). Total cholesterol and LDL were not 
altered in both groups. 
 Courcoulas et al.[46] issued a RCT that also detected a more significant reduction of TG 
and increase of HDL in RYGB compared to LWLI, with no significant differences for any other 
plasma lipid levels between the 3 treatments studied (RYGB, GB and LWLI). 
 Ikramuddin et al.[47] published another RCT that reported lower need of lipid-lowering 
medication in the RYGB compared to the medical treatment group, as well as a reduction of TG and 
increase of HDL after 1 year of follow-up. The paper with the 2 year outcomes by Ikramuddin et 
al.[48] only reported no difference in LDL levels between the 2 groups, but with a higher number of 
patients in the RYGB group achieving LDL < 100 mg/dL with no use of medication. 
 Dixon et al.[4] reported a higher prevalence of normal plasma levels for TG and HDL and 
a reduction in the use of lipid-lowering medications 5 years after GB. 
 Comparably to what is described for both T2DM and HBP, bariatric surgery in adolescents 
has very good outcomes on DLP.[51-53] 
 Inge et al.[51] has reported a remission rate of DLP among adolescent patients that 
underwent either RYGB or SG superior to 65% after 3 years of follow-up, with a substantial 
improvement in all patients with baseline DLP in the same period. 
 Likewise, Vilallonga et al.[53] studied the outcomes of RYGB in obese adolescents paired 
with a matched control group of adults and found that all patients with DLP in both groups achieved 
remission 7 years after surgery. 
 This disease, as both the other diseases approached in the present paper, shows 
improvements after failed bariatric surgery (%EWL < 25% after a follow-up ≥ 5 years), with Aminian 
et al.[22] reporting a significant reduction of TG after failed bariatric surgery and 68% of patients 
achieving the ADA goals for cholesterol – LDL levels < 100 mg/dL. 
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DISCUSSION 
 Bariatric surgery has proven to be superior to optimal medical treatment for T2DM, HBP 
and DLP treatment in obese patients, from mild obesity to morbid obesity. 
 Among the comorbidities studied, T2DM outcomes after bariatric surgery are the best 
studied and that justifies already including bariatric surgery as a therapeutic option for severely obese 
patients with T2DM in most recommendations for T2DM treatment. Regarding this obesity related 
comorbidity, most predictors have been established and there are even validated predictive scores for 
remission. The most consensual predictors of remission include disease severity criteria, like duration 
of disease and preoperative C-peptide levels, HbA1C levels and insulin use, and the surgical procedure 
used, with controversy for the 2 most used bariatric surgery procedures, RYGB and SG. Some studies 
show superiority of RYGB but others show no significant difference, although RYGB presents with 
higher remission rates. BMI is used as both a criteria of eligibility for bariatric surgery and a predictor 
of T2DM remission but remission seems to be only higher for very high BMI values, whereas 
abdominal circumference may have a better association with remission. However, further studies are 
needed before abdominal circumference can be considered a suitable replacement for BMI. 
 The next step may be expanding the recommendations of bariatric surgery as a treatment 
for T2DM to mildly obese patients (BMI 30–35 kg/m2) since superiority of bariatric surgery to 
medical treatment has been shown in this population group, although some more information on long 
term outcomes is still needed. 
 Besides only finding 1 study in non-obese patients for the present paper, that study used the 
BMI threshold for obesity of 30 kg/m2 when analysing an Asian population, which may in fact 
correspond to an obese population, so this is a group of patients in which there’s almost no information 
to even think about suggesting bariatric surgery as a T2DM treatment. 
 In terms of health costs, there’s little information and only for T2DM. Bariatric surgery’s 
superiority to medical treatment is not established, so further studies are needed. When comparing 
surgical procedures, the only study analysed found a slight advantage for SG. 
 HBP and DLP outcomes after bariatric surgery have been less studied than T2DM 
outcomes, but there’s substantial evidence that bariatric surgery is a treatment option for these 
comorbidities with great results. Effect on HBP is more pronounced for sBP and improvements in BP 
levels are well described. As for DLP, the main effects of bariatric surgery seem to be the reduction 
in TG, total cholesterol and LDL cholesterol levels and an increase in HDL cholesterol levels, 
although the evidence is better for TG and HDL changes than for the rest of the lipid profile values. 
 Bariatric surgery has also shown to decrease the need for medication in all of these 3 
comorbidities.  
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 Another important aspect of bariatric surgery is that it has shown to prevent HBP in 
normotensive patients. 
 In HBP and DLP, similarly to T2DM, bariatric surgery has shown to be more effective than 
medical treatment in mildly obese patients, with outcomes comparable to the ones in more severely 
obese patients. 
 Regarding predictors for remission of these 2 comorbidities information is very little to 
none. Further studies are needed to establish those predictors like it was done for T2DM. 
 Health care costs of bariatric surgery as a treatment for these comorbidities is also unknown 
presently and this will be an important aspect that will have to be studied if bariatric surgery is to be 
considered a therapeutic option in the future. 
 As a therapeutic option for adolescents, bariatric surgery seems to have great results as a 
treatment for T2DM, HBP and DLP but there’s still very little information and further studies on the 
outcomes of bariatric surgery in this population are needed. RYGB may be more advantageous in this 
age group compared to SG for being a potentially reversible procedure, especially until the long term 
effects of these surgeries are disclosed. 
 The 2 most used procedures, RYGB and SG, have very good results as a treatment for 
obesity and related comorbidities. There’s still some controversy regarding whether RYGB is superior 
to SG, with different findings for different studies. It seems that, if different, they are not very 
different. Although RYGB presents higher remission rates than SG, in many cases the difference is 
not statistically significant. Therefore, the choice between these two procedures may be less dependent 
of the outcomes wanted and instead be motivated by other factors. 
 Other procedures are less used because they have a risk-benefit ratio that is not as 
advantageous as it is for RYGB and SG. For instance, BPD seems to have better results than RYGB 
and SG but is also associated with more complications and GB has worse results reported than RYGB 
and SG and, although less invasive, has a high need of reoperation and removal. 
 Some less used procedures and some newly proposed procedures – DSIT, SIPS surgery or 
endoscopic procedures – have shown promising results but further investigation is needed to establish 
their role in treatment algorithms for obesity and related comorbidities. 
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CONCLUSION 
 Apart from all the advantages in managing obesity, bariatric surgery is an effective 
treatment for obesity related comorbidities. 
 Evidence of these benefits for T2DM has allowed bariatric surgery to be included in the 
treatment algorithms for this disease. With the evidence available currently, it’s even possible to 
predict with considerable accuracy which patients will best respond to this therapeutic approach. 
 For HBP and DLP promising results are also described and in the future this therapeutic 
approach can be included in the treatment strategies for those diseases, as has happened for T2DM. 
 By reducing the need for medication for all these comorbidities, bariatric surgery shows to 
have great potential in achieving better control of these diseases than the one we achieve currently. 
 The protective effect for HBP described after bariatric surgery may even allow us to use it 
as a prophylactic measure in patients with other indications for these surgical procedures. 
 All these findings support the claim that bariatric surgery has a significant impact in 
cardiovascular risk factors, with a great potential to minimize some of the greatest health problems 
presently. 
 Bariatric surgery’s superiority to the best alternative treatment available has been well 
established and so it’s important to continue researching this field in order to better establish the 
benefits of this therapeutic approach and also to determine who are the ones who can benefit the most 
from it. 
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